Veru Announces Date of 2024 Annual Meeting of Shareholders
April 01, 2024 16:05 ET
|
Veru Inc.
--2023 Form 10-K/A and Q1 2024 Form 10-Q filed today-- --2024 Annual Meeting of Shareholders will be June 18, 2024 -- MIAMI, FL, April 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late...
Veru Reschedules Annual Meeting of Shareholders
March 22, 2024 16:05 ET
|
Veru Inc.
--Restated historical financial statements expected to be filed no later than April 15, 2024-- --2024 Annual Meeting of Shareholders to follow financial statements filings-- MIAMI, FL, March 22,...
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
March 12, 2024 08:00 ET
|
Veru Inc.
MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality...
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
February 27, 2024 19:15 ET
|
Veru Inc.
MIAMI, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher...
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
February 20, 2024 08:30 ET
|
Veru Inc.
MIAMI, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality...
Veru Reports Fiscal 2024 First Quarter Financial Highlights
February 08, 2024 06:30 ET
|
Veru Inc.
—Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone— —Company to...
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
February 06, 2024 08:30 ET
|
Veru Inc.
FDA IND clearance is an important development milestone in advancing enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone ...
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
January 31, 2024 08:30 ET
|
Veru Inc.
MIAMI, FL, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for obesity, oncology, and viral induced...
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
January 25, 2024 08:30 ET
|
Veru Inc.
MIAMI, FL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology,...
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss
January 08, 2024 08:30 ET
|
Veru Inc.
MIAMI, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology,...